Large pharmaceutical targets often look like abstract financial noise to external vendors. But Otsuka’s target to hit ¥3.5 trillion by 2035 represents a concrete capital allocation roadmap. Between now and 2035, Otsuka will need specialised capabilities, from ADC manufacturing to digital phenotyping, that it cannot build in-house fast enough. Here is where supplier opportunities will emerge, and how you can position yourself to win them.
In August 2026, Otsuka Holdings broadcast its ambition to reach group sales of ¥3.5 trillion by 2035. The figure deserves attention as they represent exceptinally ambitious goals and strategies for Otsuka. The important question for technology companies, CROs, CDMOs and specialist suppliers is how Otsuka intends to add approximately ¥775 billion above its revised 2026 forecast, and which external capabilities will be required along the way.
One detail changes how the announcement should be read. Otsuka now expects 2026 revenue of ¥2.725 trillion, business profit of ¥470 billion and R&D expenditure of ¥385 billion. Its Fourth Medium-Term Management Plan, published in 2024, had set a 2028 revenue target of ¥2.5 trillion and envisaged annual R&D expenditure of roughly ¥300 billion. The currency assumptions differ considerably, so this is not a clean like-for-like demonstration that Otsuka is two years ahead of plan. It still shows that the group’s starting point has moved upwards.
Read the Target as a Capital Allocation Statement
A 2035 sales target has little practical value unless it changes where management places capital. Otsuka’s existing plan gives a clear indication. The group expects to deploy approximately ¥3.2 trillion during the five-year planning period, including around ¥1.5 trillion for R&D and roughly ¥500 billion for capital expenditure. External asset acquisitions form another important use of funds.
Otsuka’s pharmaceutical strategy is focusing on psychiatry and neurology, oncology, autoimmune and renal disease, and rare diseases. They are also examining healthcare needs related to women’s health, ageing and everyday wellbeing. This is a wider strategic frame than that of a conventional prescription-drug company. Otsuka combines major pharmaceutical operations with nutraceutical and consumer-health businesses, which can create opportunities for technologies that connect treatment, prevention, adherence and daily health management.
Current performance shows where momentum sits today. Revenue growth during the first half of 2026 was supported by products including Abilify Maintena and Asimtufii, Rexulti, VOYXACT and Lonsurf, together with royalty income. Otsuka also continued to invest in external innovation, marked by a major payment connected to the acquisition of Transcend Therapeutics and its TSND-201 programme in post-traumatic stress disorder.
Another signal of Otsuka’s strategy comes from Taiho Pharmaceutical, the group’s core oncology subsidiary. Taiho recently entered into a strategic collaboration with Fujifilm Corporation to build advanced manufacturing technology for next-generation ADCs. This relationship highlights how the group operates: while Otsuka Pharmaceutical leads CNS and renal programs, Taiho drives the group’s cancer strategy. By partnering with a Japanese CDMO titan like Fujifilm to secure complex biopharmaceutical production capacity, Otsuka is proving that advanced manufacturing and supply-chain resilience are integral parts of its ¥3.5 trillion portfolio strategy.
The ¥3.5 trillion ambition therefore does not point to one growth engine. It points to a portfolio that must keep producing new assets, new indications, stronger evidence and more efficient global execution.
What This Means for Current Suppliers
Existing suppliers should expect greater demand alongside higher standards. If you aim to tap into Otsuka’s ambitious goals and strategies for their growth programmes, you will need to operate across regions, therapeutic areas and group companies. A service designed only for a small local project may become less attractive when a programme needs global data compatibility, scalable capacity or a route into several development stages.
Evidence and real data are forever becoming more valuable. New medicines in psychiatry, neurology, renal disease, immunology, oncology and rare disease face demanding questions from regulators, payers, physicians and patients. Otsuka will need reliable translational biomarkers, patient-stratification methods, real-world evidence, health-economic analysis, pharmacovigilance, medical-affairs support and post-launch outcome data. Suppliers that can help management achieve faster development or better portfolio decisions will be more useful than suppliers that merely generate another set of technically interesting results.
Manufacturing requirements will also become more specialised. Otsuka’s portfolio increasingly creates needs around biologics, high-potency compounds, ADCs, advanced formulations, drug-device combinations, process comparability and supply resilience. The Fujifilm and Taiho collaboration illustrates the importance of securing technical capability before demand reaches commercial scale. Suppliers should be prepared to discuss capacity, redundancy, technology transfer, analytical control and lifecycle cost at an early stage.
Procurement pressure is likely to rise as investment grows. A long-standing supplier relationship will carry less weight if the service cannot support the next generation of products. Current suppliers should therefore examine which Otsuka growth driver they serve, what measurable risk they remove and how their capability can expand with the needs and programmes.
Where the New Opportunities Lie
Mental health remains a major opening. Otsuka has deep commercial and scientific experience in psychiatry, yet the field still suffers from weak biological stratification, difficult trial recruitment, subjective endpoints and poor adherence. Companies offering target-engagement tools, translational models, digital phenotyping, patient-finding methods, long-acting formulation technology, adherence support or real-world outcome measurement can make a relevant case. The strongest proposition will connect the technology to a named development or commercial problem.
Renal, autoimmune and rare diseases create a different set of needs. Small patient populations and heterogeneous disease courses place a premium on registries, specialist-site networks, biomarker strategy, natural-history data, decentralised study support and patient identification. Commercial success also depends on diagnosis, referral pathways, access and long-term patient support. A supplier that can connect clinical evidence with launch execution may be particularly useful.
Oncology creates opportunities across the full development chain, spanning tumour models, target validation, biomarker assays, combination studies, toxicology, companion-diagnostic development, high-potency manufacturing, conjugation analytics, clinical sample logistics, and post-launch evidence.
However, prospective suppliers must navigate how Otsuka structures its cancer R&D. The group’s oncology operations are primarily split between two specialised subsidiaries: Taiho Pharmaceutical, which drives late-stage clinical development, advanced manufacturing, and commercial strategy, and Astex Pharmaceuticals, a UK-based subsidiary renowned for its fragment-based drug discovery platform. Because Astex leads early-stage target identification and small-molecule discovery while Taiho manages broader development pipelines and commercialisation, a vendor’s proposal must target the exact entity handling that phase. Pitching early-stage discovery services to a Taiho commercial contact, or clinical logistics to Astex, will only create noise and no signal. Supplier proposals must align precisely with the relevant group company, its specific pipeline focus, and the correct internal decision-makers.
The broader healthcare strategy opens another category. Women’s health, healthy ageing, nutrition science, frailty, prevention and digital support sit closer to Otsuka’s identity than they do at many pharmaceutical groups. Companies with validated interventions, diagnostics or data services can present a credible case when they show clinical value, consumer relevance and a realistic path through Japan’s healthcare system. Healthy ageing is a booming market in Japan.
How a newcomer should approach Otsuka
An unfamiliar supplier should not begin with a catalogue. The first page should identify a concrete Otsuka problem. Attractive examples include shortening target validation by four months, reducing failure in biomarker selection, adding high-potency capacity, improving patient identification and preparing a difficult specialty launch.
Your proposal should answer four questions well in order to be attractive:
- Which named programme, therapeutic priority or portfolio objective does your offer support?
- What measurable delay, cost or development risk will you reduce?
- What evidence shows that your capability works in a regulated pharmaceutical setting?
- How will your work integrate with Otsuka’s Japanese and global teams?
The ambitious new goals and strategies for Otsuka are real opportunities. Navigating the internal route matters, as procurement authority rests within individual operating entities rather than corporate headquarters. Otsuka Holdings sets macro strategy, capital allocation, and group-wide financial targets, but it does not procure vendor services. Primary operational procurement sits with Otsuka Pharmaceutical, which leads the global core business in CNS, renal, and cardiovascular programs. Otsuka Pharmaceutical Factory works with clinical nutrition, IV solutions, and medical devices. Otsuka Chemical & Otsuka Techno focus on fine chemicals, advanced materials, and drug-delivery packaging.
A technology can be strategically relevant at a high level and still stall if it reaches the wrong company, the wrong functional department, or an incompatible stage of planning. New entrants must build a precise account map, secure a champion within the specific operating company, and frame their initial pitch around a manageable first project.
The 2035 goal creates a long commercial runway. It does not create an unrestricted procurement budget. Opportunity exists where an external capability advances a specific growth driver and can operate within Otsuka’s quality, governance and commercial requirements.
For international supply partners, the task is to translate technical merit into Otsuka-specific strategic relevance. Biosector helps life-science companies assess that fit, identify the correct route into Japanese pharma and prepare a credible first approach. And as Japanese companies also require strong relationships, if you don’t have a strong strategy for Japan, you need to build one!
We are happy to share our deep knowledge of Japan and help you analyse your strategies and setup for Japan. You are warmly welcome to contact us for an exploratory call.
Book a discovery meeting here!
Or contact us directly by email, here!
Comments are closed